Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

Belgium disagrees with the EMA and does not authorize the 1 mg oral form of finasteride for androgenic alopecia, citing a negative benefit-risk ratio. Despite this, some individuals in Belgium can still obtain finasteride through prescriptions, and there is debate over its mental health risks versus its benefits for hair loss and other health issues.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

The conversation discusses the effectiveness and authenticity of RU58841 purchased from Amazon, with some users suggesting buying from reputable sources like Anagen Inc. Others recommend using oral finasteride instead of RU58841 due to concerns about product legitimacy.

RU58841 can be absorbed systemically after topical application, but the study did not find immediate hormonal disruption. The study highlights the need for more research on long-term safety and effects of RU58841, as well as the importance of quality control in products from the grey market.

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

A 37-year-old woman with androgenetic alopecia is using spironolactone, oral and topical minoxidil, and considering PRP therapy due to lack of progress. She is unable to obtain finasteride, dutasteride, or bicalutamide and is exploring other options like Clascoterone and RU58841.

Finasteride's effectiveness may be reduced due to heat exposure, affecting DHT levels. Testing methods and medication storage conditions are likely factors in the unchanged DHT levels.

The conversation discusses androgenetic alopecia (AGA) and questions why treatments focus on lowering DHT levels instead of building resistance to it. It also touches on hair transplantation techniques using body hair.

Finasteride significantly improved hair density and hairline over 3.5 years, with no major side effects reported. Users discussed the effectiveness of finasteride, with some considering adding or switching to minoxidil, and shared personal experiences and timelines for seeing results.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

PP405 is discussed as a potential treatment for growing a beard in patchy areas, with some users suggesting minoxidil as an alternative. Experiences with minoxidil vary, with some users reporting significant beard growth and others seeing minimal results.

The user is exploring hair loss treatments in China, currently using finasteride and minoxidil, and is concerned about seborrheic dermatitis. Clinics are recommending selenium sulfide, doxycycline, and mesotherapy ampoules like PT88/PT66 or SP88/SP66, but the user is unsure about their effectiveness.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

There is no reliable ranking for the effectiveness of topical anti-androgens like Fluridil, RU58841, and Pyrilutamide, with limited studies available. Some users suggest Pyrilutamide may be promising based on ongoing trials, while Fluridil combined with finasteride has shown positive results for some individuals.

Microneedling with RU58841 may not be necessary since RU works topically by occupying receptors before DHT binds. RU58841 is a topical anti-androgen.

The user reports significant hair regrowth using finasteride, topical minoxidil, and dermarolling twice a week, despite poor photo quality. Another user shares their experience with oral minoxidil and finasteride, noting ongoing shedding and considering additional treatments.

RU58841 stopped hair shedding and increased hair density for the user, who experienced side effects from finasteride. The user's regimen includes RU58841, minoxidil, microneedling, Nizoral, and plans to add castor oil.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

The user experienced side effects from finasteride and is considering adding Alfatradiol or Fluridil to their regimen, which includes Minoxidil, dermarolling, and ketoconazole. Fluridil is noted to be more effective than Alfatradiol but less effective than finasteride, with mild side effects reported.

Twist-1 is being explored as a promising early-stage hair loss treatment, while Scube-3's effect on Twist-1 in breast cancer cells raises concerns about its use for hair loss. The conversation discusses the potential differences in protein effects across various cell types.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.

Low-level laser therapy (LLLT) is discussed as a supplementary treatment for hair loss, with users recommending brands like LaserCap, Ideatherapy, Capillus Pro, and iRestore Pro. Users suggest combining LLLT with treatments like minoxidil and finasteride for better results.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

RU58841 is effective for long-term hair loss treatment, often used with finasteride or dutasteride for better results. Users report varying experiences with side effects and effectiveness, with some noting improvements and others experiencing shedding or needing to adjust dosages.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

The conversation discusses natural DHT blockers like rice bran oil, which may reduce 5α-reductase activity similarly to Minoxidil and Dutasteride. One user argues that finasteride is more reliable and effective than natural alternatives.

The conversation discusses the effectiveness of topical tretinoin as a monotherapy for hair loss, with users suggesting it may not be as effective as minoxidil or finasteride. The original poster is considering other options like a phenol peel and is concerned about the risks of derma rolling.

A user shared their positive experience with a hair transplant in Turkey, using 4350 grafts, and described it as the best decision of their life. They discussed using finasteride to maintain non-transplanted hair and addressed questions about the procedure and recovery.